Our top pick for
Pyxus International Inc is a tobacco business based in the US. Pyxus International shares (PYX) are listed on the NYSE and all prices are listed in US Dollars. Pyxus International employs 3,347 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.00 - $0.00|
|50-day moving average||$0.15|
|200-day moving average||$1.65|
|Wall St. target price||$68.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-14.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Pyxus International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pyxus International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pyxus International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $75.5 million.
The EBITDA is a measure of a Pyxus International's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.6 billion|
|Operating margin TTM||2.43%|
|Gross profit TTM||$250.8 million|
|Return on assets TTM||1.24%|
|Return on equity TTM||-71.6%|
|Market capitalisation||$26.7 million|
TTM: trailing 12 months
We're not expecting Pyxus International to pay a dividend over the next 12 months.
Pyxus International's shares were split on a 1:10 basis on 28 June 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pyxus International shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pyxus International shares which in turn could have impacted Pyxus International's share price.
Over the last 12 months, Pyxus International's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pyxus International's is 1.1456. This would suggest that Pyxus International's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Pyxus International, Inc. , an agricultural company, engages in the provision of various agricultural products, ingredients, and services to businesses and customers. It offers leaf tobacco; e-liquids used in vaporizers, electronic cigarettes, and other vaping hardware and accessories; and industrial hemp-derived cannabidiol products. The company was formerly known as Alliance One International, Inc. and changed its name to Pyxus International, Inc. in September 2018. Pyxus International, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.